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Background: The Incontinence Quality of Life (I-QOL) questionnaire is a commonly used and validated
incontinence specific QOL instrument. The objective of this study is to develop an algorithm to map I-QOL to the
Assessment of Quality of Life (AQoL) 8D utility instrument in patients with idiopathic overactive bladder (iOAB).
Methods: I-QOL and AQoL-8D scores were collected in a survey of 177 Australian adults with urinary incontinence
due to iOAB. Three statistical methods were used for estimation, namely ordinary least squares (OLS) regression, the
robust MM-estimator, and the generalised linear models (GLM). Each included a range of explanatory variables.
Model performance was assessed using key goodness-of-fit measures in the validation dataset.
Results: The I-QOL total score and AQoL-8D utility scores were positively correlated (r = 0.50, p < 0.0001). Similarly,
the three sub-scales of the I-QOL were correlated with the eight dimensions and two super-dimensions of the
AQoL-8D. The GLM estimator, with I-QOL total score as the explanatory variable exhibited the best precision
(MAE = 0.15 and RMSE = 0.18) with a mapping function given by AQoL-8D = exp(−1.28666 + 1.011072*I-QOL/100).
Conclusions: The mapping algorithm developed in this study allows the derivation of AQoL-8D utilities from I-QOL
scores. The algorithm allows the calculation of preference-based QOL scores for use in cost-utility analyses to assess
the impact of interventions in urinary incontinence.
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Urinary incontinence (UI) is defined as any involuntary
loss of urine. UI occurs at all ages, however, both preva-
lence and incidence of UI increase with age [1,2]. Incon-
tinence is a significant health issue that has physical,
social and economic implications on patients, as well as
the broader community [3]. A study in the United States
estimated the total cost associated with UI in the US as
US$19.5 billion [4]; an amount that was greater than the
sum of the annual direct costs of breast, ovarian, cervical
and uterine cancers [5].* Correspondence: Tan_Jonathan@allergan.com
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unless otherwise stated.Idiopathic overactive bladder syndrome (iOAB) is a
common cause of urinary incontinence. As defined by
the International Continence Society, iOAB is characte-
rized by the presence of urinary urgency, often with UI,
increased frequency (>8 voids per day), and nocturia
(ie, interruption of sleep ≥1 time/night to urinate) [6]. Uri-
nary incontinence due to iOAB is to be distinguished from
other etiologies of incontinence such as neurogenic de-
trusor overactivity, where bladder dysfunction is due to a
known neurological condition (eg, spinal cord injury), or
stress incontinence, which is the involuntary loss of urine
on physical exertion.
The ability to control one’s elimination functions is a
highly valued health outcome. Urinary incontinence and
other iOAB symptoms have adverse impacts on multi-
ple domains of health-related quality of life (HRQOL),td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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due to leakage), sexual and interpersonal relationships, so-
cial interactions, and mental wellbeing [7]. The Australian
Health Omnibus Survey found severe UI to be associated
with a significant disutility of 0.32 based on the Assess-
ment of Quality of Life (AQoL) and the EuroQOL five di-
mensions (EQ-5D) instruments [8]. Similarly, a national
survey in the US, found that, after standardising for other
personal characteristics, patients with UI had clinically
and significantly poorer SF-36 scores across all domains
compared to patients without UI [9].
The measurement and monitoring of HRQOL has be-
come a key component for assessing the cost-effectiveness
of medical interventions and health programs in clinical
medicine research [10]. One common response to this
need has been to include a disease specific instrument
which has been specifically designed to measure dimen-
sions of health which are important for the specific
disease.
However, condition-specific measures do not provide
‘utility’ scores, which are necessary for the estimation of
quality adjusted life years (QALYs) which are the unit of
outcome in cost-utility analyses (CUA). CUA has be-
come of increasing importance in the allocation of finite
healthcare resources. For example, in Australia, Canada,
and the United Kingdom, cost-per-QALY ratios are used
by healthcare authorities in their appraisal of drug in-
terventions. Consequently, a common approach to over-
come this limitation is to develop mapping algorithms
that transform condition-specific HRQOL scores into
preference-based HRQOL utilities [11]. While generic
utility instruments such as the SF-6D and EQ-5D can be
utilised in any study regardless of the condition, this
versatility comes at the expense of sensitivity to certain
aspects of HRQOL that may be of importance to the
conditions being studied. In the case of incontinence,
a number of studies have shown that commonly used
generic HRQOL instruments and multi-attribute util-
ity instruments (MAUIs) are relatively insensitive to
health dimensions that are affected by the treatment
of UI [12–14]. In particular, these instruments fail to
capture the full effect of poor sleep and psycho-social
outcomes that are affected by incontinence. In the key stu-
dy by McCallum [13], several MAUIs (ie, AQoL. EQ-5D,
HUI3, SF-6D) were compared and the AQoL was iden-
tified as the instrument of choice for incontinence studies,
as it provided the best coverage and sensitivity to HRQOL
aspects impacted by incontinence. For this reason, the
AQoL was selected for use in the present study in com-
bination with the Incontinence Quality of Life Question-
naire (I-QOL). These two instruments are described in the
Methods section.
The mapping algorithm will enable I-QOL scores ob-
served in clinical trials for UI to be transformed intoutility scores and facilitate the conduct of economic evalu-
ations to inform decision decision-making with regards to
healthcare resource allocation.Methods
Data
A cross-sectional survey (N = 1341) of individuals with
iOAB in Australia, Canada, France, Germany, Italy, Spain,
United Kingdom and the United States was conducted be-
tween December 2012 and March 2013 [15]. In only the
Australian subgroup, both the I-QOL and AQoL instru-
ments were administered. This data has been used in the
present study to develop a mapping algorithm between
the I-QOL and AQoL-8D.
Patients were recruited through the Quintiles (a con-
tract clinical research organization) patient databases and
registries. These registries are a voluntary medication
monitoring service that allows interested individuals to be
contacted to participate in medical surveys and studies
relevant to their medical conditions. Respondents were
screened to ensure that only subjects ≥18 years of age,
with previously diagnosed iOAB, or those who had symp-
toms of iOAB, were allowed to participate in the survey.
Exclusion criteria included a predominance of stress UI,
pregnancy, a history of neurological disorders, history of
bladder disorders, including bladder stones and bladder
outlet obstruction, a history of bladder or prostate cancer,
and bladder reconstructive surgery.
Patient information was based on self-reported data
through an online survey. Patients were granted access
to the survey only after providing informed consent on-
line. The study protocol was approved by the respective
institutional review board, Ethical and Independent Re-
view Services.Instruments
The incontinence quality of life questionnaire (I-QOL)
The I-QOL, developed by Wagner [16] and Patrick [17],
is a commonly used self-reported HRQOL instrument
for people with UI. The I-QOL consists of 22 items, all
of which use a five-point ordinal response scale in which
1 = extremely, 2 = quite a bit, 3 = moderately, 4 = a little,
and 5 = not at all.
The 22 items can be further grouped into 3 subscales:
Avoidance and Limiting Behaviour (8 items), Psycho-
social Impacts (9 items), and Social Embarrassment (5
items). The total I-QOL and 3 subscale scores are calcu-
lated by summing the unweighted item score and trans-
forming them to a 100 point scale where 0 =most severe,
and 100 = no problem . The instrument has been widely
used and has been successfully validated for people with
UI [18,19].
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Building upon the earlier AQoL MAUIs (ie, AQoL-4D
and AQoL-6D), the AQoL-8D has significantly increased
the content for health states pertaining to social and psy-
chological problems [20], which are relevant in the study
of incontinence. The AQoL-8D contains 35 items, these
are grouped into eight dimensions (Independent Living,
Relationships, Mental Health, Coping, Pain, Senses, Hap-
piness and Self-Worth), which may be further grouped
into two ‘super-dimensions’ (ie, physical and psychosocial/
mental). With four to six response levels for each of the
35 items, this allows for 2.37 × 1023 possible health states.
The time trade-off method was used for the preference-
based valuation of AQoL-8D health states. Utility scores
were calculated from the 35 items using the AQoL-8D
scoring algorithm (Version 13), available at www.AQoL.
com.au. Although AQoL-8D has not been widely used to
date, it has been successfully tested for reliability and val-
idity [21]. Recent evidence indicates that AQoL-8D has
greater sensitivity to the psycho-social dimensions of QOL
(which are relevant in the study of incontinence) than the
other utility instruments in common use [22].
Statistical analysis
The survey data were used to estimate a mapping al-
gorithm between the I-QOL and AQoL-8D that can be
applied for other studies. The approach is a widely used
strategy in mapping analysis and is referred to in the lit-
erature as the ‘transfer to utility regression technique’
[23].In this study we adopted two model specifications.
The first used I-QOL total scores and the second used
the I-QOL subscale scores as the independent variable
(s). Two demographic variables (age and gender) were
included in the models which were specified as the fol-
lowing equations:
 Model 1: I-QOL total score model
AQoL8D ¼ α0 þ β ⋅ IQOLþ α1 ⋅AGE þ α2 ⋅GENDERþ μ
 Model 2: I-QOL subscale score model
AQoL8D ¼ α0 þ γ1 ⋅ IQOLPS þ γ2 ⋅ IQOLSE þ γ3
⋅ IQOLALB þ α1 ⋅AGE þ α2 ⋅GENDERþ μ
where AQoL8D is the AQoL-8D utility; IQOL is the
I-QOL total score; IQOLPS, IQOLSE, and IQOLALB are
the scores of Psychosocial Impacts scale, Social Embar-
rassment scale, and Avoidance and Limiting Behaviour
scale respectively; AGE is a continuous variable for
the respondents’ age; GENDER is a dummy variable that
equals 1 if the respondent is male and 0 otherwise;α0 is a constant, α1, α2, β, and γ are the coefficients to
be estimated, μ is the error term. The squared terms of
the I-QOL (total/scale) scores were also considered in
the relevant models. In the final models, only the ex-
planatory variables which were statistically significant
(p ≤ 0.05) were retained. A stepwise regression technique
with forward selection [24] was used to choose the “best”
combination of predictors.
Three statistical techniques were adopted in the study
to estimate the two models.
1. Firstly, an ordinary least squares (OLS) estimator
was used. This has been the most widely used
technique in the literature [11,23].
2. Secondly, an effective robust estimator, the MM
estimator [25] was used. This has recently been
proposed for mapping analysis by Chen [26]. The
justification for using robust estimators lies in the
fact that the OLS estimator is highly sensitive to
sample outliers.
3. Lastly, the generalised linear model (GLM) was
used, which allows for the non-normal distribution
of dependent variables (e.g. left/negatively skewed
utility scores) [27]. For the GLM estimation a choice
must be made between the type of ‘family estimate’
(e.g. Gaussian, inverse Gaussian, binomial, gamma)
and the link function (e.g. identity, log, logit, cloglog,
log-log, log-complement, power).
Based on the goodness-of-fit results in the validation
analysis, the Gaussian family with log link was chosen as
the most appropriate method.
Other popular estimators that are widely adopted in
the mapping analysis also include the Tobit estimator,
the censored least absolute deviations (CLAD) estimator,
and the Two-Part Model (2 PM) which especially take
into account censoring issues (e.g. a high proportion of
respondents report full health with a utility of 1) [28].
These three estimators are not used in this analysis be-
cause sample censoring is not an issue when AQoL-8D
utility was scored in this study.
Model performance was assessed using the internal
data, due to the lack of availability of an external valid-
ation dataset. The full sample was divided equally into five
groups using computer-generated random numbers. In
each group, 80% of the sample was assigned to the “esti-
mation sample” that was used to generate the mapping al-
gorithm, while the remaining 20% of the sample (assigned
to the “validation sample”) was used to predict AQoL-8D
utilities based on the above algorithm. This procedure was
repeated five times, so that each of the five random groups
was used in the estimation and validation exercises.
Goodness-of-fit was examined by the mean absolute
error (MAE) and the root mean square error (RMSE).
Table 1 General characteristics of patients
Patient characteristic N = 177
Mean age, years 56.5 (SD: 13.7)
Females 85.3%
Caucasian 95.7%
Mean years since diagnosis of iOAB, n (%)
• <1 year 28 (16)
•1-4 years 105 (59)
• 5-10 years 28 (16)
• >10 years 16 (9)
History of anti-cholinergic medication use, n (%)
• Used previously 157 (89)
• Failed 71 (40)
Education, n (%)
• Elementary/High School 129 (73)
• College/University degree 35 (20)
• Post-graduate degree 13 (7)
Income, n (%)
• ≤$50,000 91 (51)
• $50,001 to $100,000 35 (20)
• >$100,000 24 (14)
• Did not disclose 27 (15)
Urinary incontinence, mean episodes per day (SD) 2.5 (2.2)
Micturitions, mean episodes per day (SD) 8.5 (4.2)
Nocturiaa, n (%) 95 (53.7)
Urgency, mean episodes per day (SD) 3.2 (3.4)
I-QOL score, mean (SD) 78.0 (18.3)
AQoL-8D utility, mean (SD) 0.62 (0.21)
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with the lowest combination of MAE and RMSE values.
When there was a disagreement between the optimal cho-
sen combination, the procedure used by Kay [29] was
adopted, which used the RMSE of the validation analysis
as the key criteria to measure model performance. All
analyses were estimated in STATA version 12.1 (StataCorp
LP, College Station, Texas, USA).
Results
Patient characteristics
A total of 254 subjects were recruited through the
Australian centres. Of these, 177 iOAB subjects with
UI completed the I-QOL and AQoL instruments and
were included in the present study. As shown in Table 1,
the mean age of patients was 56 (SD: 14), with females
comprising 85% of the samples. Participants experienced
an average of 2.5 incontinence episodes per day (range 1
to 15, SD 2) and 1.9 nocturia episodes per night. The
respondents had a mean I-QOL total score of 77.99 (SD
18.34, range 23.86 to 100), and a mean AQoL-8D utility of
0.62 (SD 0.21, range 0.13 to 0.99), which is comparable to
utility estimates previously reported in incontinent pa-
tients in Australia [8].
The distribution of the I-QOL total score and AQoL-
8D utility of the study respondents is shown in Figure 1.
The correlations between I-QOL scores and AQoL di-
mension values and utility are presented in Table 2. Not-
ably, all I-QOL subscales are significantly correlated with
AQoL-8D dimensions (p < 0.0001). The correlation ranges
from 0.22 (between Avoidance and Limiting Behaviour in
I-QOL and Mental Health in AQoL-8D) to 0.47 (between
Avoidance and Limiting Behaviour in I-QOL and Inde-
pendent Living in AQoL-8D). Overall, the I-QOL total
score and AQoL-8D utility show moderately correlation
with a coefficient of 0.50.
Mapping results
In all of the model specifications the squared term of the
I-QOL score and the age and gender variables were sta-
tistically insignificant and are not included in the results
reported below. The goodness-of-fit statistics for the re-
maining models and statistical methods are reported in
Table 3. The first three columns show the predicted mean
minimum, maximum AQoL-8D utilities. With the excep-
tion of the MM-estimator, the predicted mean utilities,
based on OLS estimators and GLM estimators, are either
identical or very close to the observed (sample) mean util-
ity. However, it should be noted that all predicted utilities
tend to over predict the lowest, and under predict the
highest boundary of the observed utility. This is not un-
common in the transformation analysis [30-32].
The MAE and RMSE are reported in the last two
columns of Table 3. The MAE ranged from 0.1461 to0.1479, whilst the RMSE varied from 0.1795 to 0.1831.
Although not reported in Table 2, the R-squared statis-
tics for both models estimated using OLS were 0.2493
(Model 1) and 0.2509 (Model 2), which are within the
acceptable range for mapping algorithms [11]. The MAE
and RMSE were very similar across the various combi-
nations of models and methods, with Model 2 (using I-
QOL subscale scores as key explanatory variables) based
on GLM estimator having the lowest MAE (0.1461) and
lowest RMSE (0.1795).
The goodness-of-fit results from the validation analysis
are reported in Table 4. As shown in columns 4 and 5,
the minimum MAE was obtained using the OLS esti-
mate with Model 1, while the best fit using the RMSE
criterion was achieved with the GLM estimate on Model
1. The relative small sample size, and the small variance
in MAE/RMSE between models may have led to the dif-
fering conclusions between the full sample and validation
analysis. As discussed in the Methods section, when there
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Figure 1 Kernal density of AQoL-8D utility and I-QOL total score.
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mended that the mapping algorithm, based on I-QOL
total score using GLM estimator (with Gaussian family
and log link), should be adopted. From Table 4 this is
given in the following equation:
AQoL−8D utility ¼ exp −1:28666 þ 1:011072  IQOL=100ð Þð Þ:
The mapping equations corresponding to the goodness-
of-fit results (shown in Table 3) are reported in Table 5.
The scattergram correlation between the original AQoL-
8D utility and the utility predicted by the preferred modelTable 2 Correlations between I-QOL and AQoL-8D
I-QOL subscale scores
Avoidance & limiting behaviour Ps
AQoL-8D dimensions
Independent Living 0.4698 0.4
Relationships 0.3104 0.3









AQoL-8D utility 0.4384 0.
All correlation are significant (p < 0.0001).is shown in Figure 2. The STATA commands for using the
algorithm is given in Additional file 1.Discussion and conclusion
With the increasing importance of health technology as-
sessment in health system reforms and decision-making,
the measurement of HRQOL are increasingly common-
place in clinical trials and public health intervention pro-
grams. However, respondent burden limits the number
and type of QOL instruments included in clinical stu-
dies. Mapping analysis provides a method for transform-
ing condition-specific quality of life scores into utilitiesI-QOL












Table 3 Goodness-of-fit results for mapping from I-QOL score to AQoL-8D utility score
Mean AQoL-8D (1) Min AQoL-8D (2) Max AQoL-8D (3) MAE (4) RMSE (5)
Observed 0.6176 0.1331 0.9888 ― ―
Method 1: OLS
Model 1 0.6176 0.3092 0.7430 0.1463 0.1808
Model 2 0.6176 0.2854 0.7243 0.1472 0.1806
Method 2: MM-estimator
Model 1 0.6185 0.2844 0.7543 0.1465 0.1810
Model 2 0.6231 0.2644 0.7079 0.1479 0.1831
Method 3: GLM†
Model 1 0.6176 0.3516 0.7591 0.1463 0.1804
Model 2 0.6174 0.3254 0.7387 0.1461 0.1795
MAE: mean absolute error; RMSE: root mean squared error.
†The Gaussian family with log link was used.
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study provides a mapping algorithm to transform the
I-QOL total score, commonly used in incontinence clin-
ical trials [33,34], to the AQoL-8D utility to enable the es-
timation of health state utility values.
In the present study, several model specifications and
statistical methods were assessed. The best model result
was obtained using the I-QOL total score as the key ex-
planatory variable (Model 1), with the algorithm estima-
ted with a robust GLM estimator (with Gaussian family
and log link). As shown in Table 4, the model using the
three I-QOL subscales also showed significant predictive
ability. In particular, the Psychosocial Impact and Social
Embarrassment subscales both showed significant asso-
ciations, with the Psychosocial Impact subscale showing
the strongest correlation with AQoL-8D (r = 0.48). This
confirms the appropriateness of using the AQoL-8D to
measure utility, as psycho-social QOL has been shown
to be of importance for patients with UI and previousTable 4 Goodness-of-fit results from validation analysis
Mean AQoL-8D (1) Min AQoL-8D (2)
Observed 0.6176 0.1331
Method 1: OLS
Model 1 0.6172 0.2858
Model 2 0.6186 0.2945
Method 2: MM-estimator
Model 1 0.6182 0.2565
Model 2 0.6233 0.2742
Method 3: GLM†
Model 1 0.6168 0.3291
Model 2 0.6180 0.3235
MAE: mean absolute error; RMSE: root mean squared error.
†The Gaussian family with log link was used.studies have shown AQoL-8D to be the most sensitive
MAU instrument to psychosocial health among six gen-
eric preference-based instruments [22].
To date only one published study has mapped the
I-QOL to preference-based HRQOL instruments (EQ-5D)
[29]. The preferred model in the present study displays
greater precision with both lower MAE and RMSE values
(0.15 and 0.18, respectively vs. 0.17 and 0.22 in Kay et al.).
The study by Kay [29] adopted the 2 PM statistical me-
thod, due to the ceiling effects with the use of EQ-5D
where 46% of subjects reported full health. As discussed
in the Methods section, 2 PM was not considered in this
study as no patient in this sample had full health on the
AQoL-8D scale. In turn, the larger MAE and RMSE values
in the study by Kay [29] are probably attributable to the
methodological disadvantage of coping with the presence
of significant ceiling effects. Consistent with the results in
Kay [29] age and non-linear terms of I-QOL scores were








Table 5 Mapping equations from I-QOL score to AQoL-8D utility
OLS MM-estimator GLM‡
Coeff. SE Coeff. SE Coeff. SE
Model 1 (using I-QOL total score)
I-QOL† 0.5697422 0.0747355** 0.6172410 0.0730065** 1.0110720 0.1441272**
Constant 0.1732625 0.0598689** 0.1370898 0.0615673* −1.2866600 0.1225249**
Model 2 (using I-QOL subscale scores)
I-QOL-PS† 0.3469097 0.1252910** 0.5913308 0.0627952** 0.6703759 0.2472593**
I-QOL-SE† 0.1985825 0.0938378* 0.3521859 0.1691879*
Constant 0.1787669 0.0690521** 0.1165455 0.0564778* −1.3254590 0.1526178**
SE - standard errors. *p < 0.05, **p < 0.01. †The I-QOL total/subscale scores included in the regression model were calculated as original scores divided by 100.
‡The Gaussian family with log link was used.
I-QOL-PS: I-QOL Psychosocial Impacts; I-QOL-SE: I-QOL Social Embarrassment.
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sample size is modest, although mapping studies with
smaller sample sizes have been reported upon in the lit-
erature [11,23]. Nevertheless, it is desirable that further
mapping studies are conducted using larger samples to
test the reliability of the mapping algorithm reported
here. Secondly, the model performance is validated with
internal data. Since mapping is data dependent, the choice
of response sample may influence the calibration of map-
ping algorithms. A cross-validation study should there-
fore be conducted when an external dataset is available.
Thirdly, the predicted AQoL-8D utilities do not capture
the full range of observed AQoL-8D utilities. The over-
prediction of the lowest utilities and the under-prediction






















Note: Observed AQoL-8D = 0 + 1*Predicted AQoL-8D
Figure 2 Scatter correlation between observed and predicted AQoL-8Despite these qualifications, the goodness-of-fit mea-
sures reported in this study are within the ranges of
previously published studies [11]. It is recognized that
transformations cannot create information about dimen-
sions which are not included in the instrument. As such
the transformation of the I-QOL is the second best alter-
native to the use of an appropriate multi attribute utility
instrument that is able to adequately capture changes in
aspects of HRQOL affected by UI.
Results reported here indicate that the I-QOL can be
mapped to AQoL-8D utility with acceptable precision at
the group level in patients with urinary incontinence
due to iOAB. While both aggregated and individual level
predictions of AQoL-8D utilities can be incorporated
within the CUA, it is recommended that the group level
predicted utility is more suitable [11]..6 .7 .8
 I-QOL score (GLM)(Model 1)
Fitted values
D utilities.
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